OM:XSPRAY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. More Details


Snowflake Analysis

Exceptional growth potential with adequate balance sheet.

Share Price & News

How has Xspray Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XSPRAY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.7%

XSPRAY

-5.4%

SE Biotechs

-6.0%

SE Market


1 Year Return

99.2%

XSPRAY

15.1%

SE Biotechs

6.2%

SE Market

Return vs Industry: XSPRAY exceeded the Swedish Biotechs industry which returned 15.1% over the past year.

Return vs Market: XSPRAY exceeded the Swedish Market which returned 6.2% over the past year.


Shareholder returns

XSPRAYIndustryMarket
7 Day-3.7%-5.4%-6.0%
30 Day-19.6%-18.6%-6.3%
90 Day-33.2%-6.4%1.7%
1 Year99.2%99.2%15.9%15.1%8.0%6.2%
3 Year286.8%286.8%32.0%29.3%22.4%9.3%
5 Yearn/a42.0%34.6%45.6%17.4%

Price Volatility Vs. Market

How volatile is Xspray Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xspray Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XSPRAY (SEK128.5) is trading below our estimate of fair value (SEK4365.01)

Significantly Below Fair Value: XSPRAY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XSPRAY is unprofitable, so we can't compare its PE Ratio to the SE Biotechs industry average.

PE vs Market: XSPRAY is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XSPRAY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XSPRAY is overvalued based on its PB Ratio (6.2x) compared to the SE Biotechs industry average (4.9x).


Next Steps

Future Growth

How is Xspray Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

111.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XSPRAY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).

Earnings vs Market: XSPRAY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: XSPRAY's is expected to become profitable in the next 3 years.

Revenue vs Market: XSPRAY's revenue (67.9% per year) is forecast to grow faster than the Swedish market (3.4% per year).

High Growth Revenue: XSPRAY's revenue (67.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: XSPRAY's Return on Equity is forecast to be very high in 3 years time (58.3%).


Next Steps

Past Performance

How has Xspray Pharma performed over the past 5 years?

-54.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XSPRAY is currently unprofitable.

Growing Profit Margin: XSPRAY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XSPRAY is unprofitable, and losses have increased over the past 5 years at a rate of 54.9% per year.

Accelerating Growth: Unable to compare XSPRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XSPRAY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).


Return on Equity

High ROE: XSPRAY has a negative Return on Equity (-15.66%), as it is currently unprofitable.


Next Steps

Financial Health

How is Xspray Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: XSPRAY's short term assets (SEK141.6M) exceed its short term liabilities (SEK19.2M).

Long Term Liabilities: XSPRAY's short term assets (SEK141.6M) exceed its long term liabilities (SEK3.6M).


Debt to Equity History and Analysis

Debt Level: XSPRAY is debt free.

Reducing Debt: XSPRAY has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XSPRAY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XSPRAY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Xspray Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XSPRAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XSPRAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XSPRAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XSPRAY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XSPRAY's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Per Andersson (53 yo)

14.75yrs

Tenure

kr2,675,000

Compensation

Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp ...


CEO Compensation Analysis

Compensation vs Market: Per's total compensation ($USD302.51K) is about average for companies of similar size in the Swedish market ($USD414.13K).

Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Per Andersson
Chief Executive Officer14.75yrskr2.68m1.16%
SEK 25.9m
Mustafa Demirbüker
Co-Founder and Science Directorno datano datano data
Kerstin Hasselgren
Chief Finance Officer1.42yrsno data0.026%
SEK 591.7k
Gérald Jesson
Vice President of Operationsno datano datano data
Helene Dérand
Sales & Marketing Directorno datano datano data
Charlotta Liljebris
Chief of Research & Development2.75yrsno data0.0070%
SEK 157.9k

2.8yrs

Average Tenure

56yo

Average Age

Experienced Management: XSPRAY's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Maris Hartmanis
Independent Director5.75yrskr155.00k0.17%
SEK 3.8m
Michael Jensen
Independent Chairman of the Board7.75yrskr280.00k0.27%
SEK 6.0m
Carl-Johan Spak
Independent Director5.75yrskr125.00kno data
Torbjörn Koivisto
Independent Director3.75yrskr140.00kno data
Christine Lind
Independent Director1.42yrskr140.00k0.023%
SEK 526.1k
Gunnar Gårdemyr
Independent Director1.42yrskr140.00k0.026%
SEK 578.5k

4.8yrs

Average Tenure

57.5yo

Average Age

Experienced Board: XSPRAY's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XSPRAY insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13%.


Top Shareholders

Company Information

Xspray Pharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xspray Pharma AB (publ)
  • Ticker: XSPRAY
  • Exchange: OM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr2.240b
  • Shares outstanding: 17.03m
  • Website: https://www.xspraypharma.com

Number of Employees


Location

  • Xspray Pharma AB (publ)
  • Råsundavägen 12
  • Solna
  • Stockholm County
  • 169 67
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XSPRAYOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKSep 2017
0GHZLSE (London Stock Exchange)YesShare CapitalGBSEKSep 2017
6XPBST (Boerse-Stuttgart)YesShare CapitalDEEURSep 2017

Biography

Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was form ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/29 21:53
End of Day Share Price2020/10/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.